IL6 and congenital rubella syndrome: For safety, given the high IL-6 levels induced by CAR T cells infused into CD20 depleted animals, and potential CRS development, future studies should incorporate potential CRS inhibitory drugs as are commonly used in clinical CAR-T cell trials.